Glioma Cell Migration and Invasion
Led by Steven Rosenfeld, MD, PhD at New York-Presbyterian Hospital/Columbia University Medical Center

Patients diagnosed with glioblastoma that receive treatment with anti-angiogenic medications have enjoyed a longer life expectancy than those receiving other treatments. Despite this benefit, in about 50% of patients, the tumors change from local to diffused, highly-invasive, chemotherapy-resistant and fatal. Dr. Rosenfeld will use mice to study why this change happens and how to potentially block it.

Rosenfeld is on VABC’s Medical Advisory Board.

 
Click here for a full list of research grants funded by Voices Against Brain Cancer.